Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Melatonin  COVID-19 treatment studies for Melatonin  C19 studies: Melatonin  Melatonin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy
Cross et al., Endocrine Practice, doi:10.1016/j.eprac.2021.06.001 (Review)
Cross et al., Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy, Endocrine Practice, doi:10.1016/j.eprac.2021.06.001 (Review)
Jun 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Review of the potential benefits of melatonin for COVID-19.
Cross et al., 10 Jun 2021, peer-reviewed, 4 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperMelatoninAll
Abstract: Endocrine Practice 27 (2021) 850e855 Contents lists available at ScienceDirect Endocrine Practice journal homepage: www.endocrinepractice.org Review Article Melatonin for the Early Treatment of COVID-19: A Narrative Review of Current Evidence and Possible Efficacy Kristina M. Cross, MS 1, *, Dylan M. Landis, BA 1, Laveena Sehgal, BS 1, J. Drew Payne, DO 2 1 2 School of Medicine, Texas Tech University Health Science Center, Lubbock, Texas Department of Internal Medicine, Texas Tech University Health Science Center, Lubbock, Texas a r t i c l e i n f o a b s t r a c t Article history: Received 31 March 2021 Received in revised form 24 May 2021 Accepted 2 June 2021 Available online 10 June 2021 Objective: To discuss the use of melatonin as an early treatment option on the first day of diagnosis for COVID-19. Methods: Medical Subject Headings terms “COVID-19” and “viral diseases” were manually searched on PubMed, and relevant articles were included. Results: The results showed that melatonin acts to reduce reactive oxygen speciesemediated damage, cytokine-induced inflammation, and lymphopenia in viral diseases similar to COVID-19. Conclusion: These conclusions provide evidence for potential benefits in melatonin use for COVID-19 treatment as early as the day of diagnosis. © 2021 AACE. Published by Elsevier Inc. All rights reserved. Key words: melatonin COVID-19 viral diseases SARS-CoV-2 antioxidant anti-inflammatory agent
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit